Clinical characteristics in patients with SARS‐CoV‐2/HBV co‐infection

Li-ping, Chen; Huang, Shaoping; Yang, Jincheng; Cheng, Xin; Shang, Zhiyin; Lu, Hongzhou; Cheng, Jun

doi:10.1111/jvh.13362

Cited by 58 publications

(74 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, only patients with SARS-CoV-2 and chronic HBV coinfection were enrolled. Although we did not compare coronavirus disease 2019 (COVID-19) patients with HBV coinfection and patients with SARS-CoV-2 infection alone in our study, Chen et al 1 found no significant differences in liver function parameters, discharge rate, length of stay, severity, and mortality between COVID-19 patients with and without HBV infection. We fully agree with the comment by Lv et al that “the clinical stage of included patients cannot be determined”.…”

contrasting

confidence: 56%

Liver Function Should Be Monitored When Treating COVID-19 in Chronic HBV-Infected Patients

Zou

Fang

Huang

2020

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

contrasting

confidence: 56%

Liver Function Should Be Monitored When Treating COVID-19 in Chronic HBV-Infected Patients

Zou

Fang

Huang

2020

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

“…However, this appears to be rare occurrence with only a single case report of a patient with possible HBV reactivation (50). The limited evidence suggests that chronic HBV infection is not associated with worse outcomes compared to those without HBV infection (51,52).…”

Section: Hepatitis Bmentioning

confidence: 98%

Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care

et al. 2021

View full text Add to dashboard Cite

Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus that emerged in late 2019, is posing an unprecedented challenge to global health. Coronavirus disease 2019 (COVID-19), the clinical disease caused by SARS-CoV-2, has a variable presentation ranging from asymptomatic infection to life-threatening acute respiratory distress syndrome and multiorgan failure. Liver involvement is common during COVID-19 and exhibits a spectrum of clinical manifestations from asymptomatic elevations of liver function tests to hepatic decompensation. The presence of abnormal liver tests has been associated with a more severe presentation of COVID-19 disease and overall mortality. Although SARS-CoV-2 RNA has been detected in the liver of patients with COVID-19, it remains unclear whether SARS-CoV-2 productively infects and replicates in liver cells and has a direct liver-pathogenic effect. The cause of liver injury in COVID-19 can be attributed to multiple factors, including virus-induced systemic inflammation, hypoxia, hepatic congestion, and drug-induced liver disease. Among patients with cirrhosis, COVID-19 has been associated with hepatic decompensation and liver-related mortality. Additionally, COVID-19's impact on health care resources can adversely affect delivery of care and outcomes of patients with chronic liver disease. Understanding the underlying mechanisms of liver injury during COVID-19 will be important in the management of patients with COVID-19, especially those with advanced liver disease. This review summarizes our current knowledge of SARS-CoV-2 virus-host interactions in the liver as well the clinical impact of liver disease in COVID-19. (Hepatology 2021;74:1088-1100). Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was officially declared a pandemic by the World Health Organization in March 2020. COVID-19 has a variable presentation ranging from an asymptomatic illness to severe pneumonia with acute respiratory distress syndrome, accompanied by multiorgan failure, shock, and severe thromboembolic events. The most common clinical features reported among patients who were symptomatic include fever, dry cough, shortness of breath, anosmia and ageusia, and diarrhea.Coronaviruses are enveloped, positive-sense, singlestranded RNA viruses belonging to the Coronaviridae family, responsible for mild upper respiratory and gastrointestinal tract infections in humans. Two emerging members of the Coronaviridae family were previously demonstrated to pose a major public health threat, namely the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle Eastern respiratory syndrome coronavirus (MERS)-CoV. In December 2019, the first cases of viral pneumonia caused by a novel coronavirus (SARS-CoV-2) was reported. Over the ensuing months, the virus has rapidly spread globally, resulting in over 50 million infected persons and one million deaths, exceeding other major infectious causes of death worldwide.

show abstract

“…Liver injury was observed in a small proportion of patients (14, 13.33%), which is within the range of incidence in patients with COVID-19 alone, and four (28.57%) patients with liver dysfunction progressed to acute-on-chronic liver failure. Moreover, other retrospective studies have shown that liver injury in COVID-19 patients with HBV coinfection also presents with varying degrees of elevated transaminases (such as ALT, AST, γ-glutamyl transferase, and total bilirubin), but most studies have found no significant difference in the degree of liver damage compared to that in patients with COVID-19 alone[ 22 - 26 ]. The characteristics of liver injury in patients with SARS-CoV-2 and HBV coinfection are listed in Table 1 .…”

Section: Impact Of Hbv On Covid-19mentioning

confidence: 99%

Interaction between hepatitis B virus and SARS-CoV-2 infections

Xiang¹,

Zheng²

2021

WJG

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has become a global pandemic and garnered international attention. The causative pathogen of COVID-19 is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel, highly contagious coronavirus. Numerous studies have reported that liver injury is quite common in patients with COVID-19. Hepatitis B has a worldwide distribution as well as in China. At present, hepatitis B virus (HBV) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma. Because both viruses challenge liver physiology, it raises questions as to how coinfection with HBV and SARS-CoV-2 affect disease progression and mortality. Is there an increased risk of COVID-19 in patients with HBV infection? In this review, we summarize the current reports of SARS-CoV-2 and HBV coinfection and elaborate the interaction of the two diseases. The emphasis was placed on evaluating the impact of HBV infection on disease severity and clinical outcomes in patients with COVID-19 and discussing the potential mechanism behind this effect.

show abstract

Clinical characteristics in patients with SARS‐CoV‐2/HBV co‐infection

Cited by 58 publications

References 11 publications

Liver Function Should Be Monitored When Treating COVID-19 in Chronic HBV-Infected Patients

Liver Function Should Be Monitored When Treating COVID-19 in Chronic HBV-Infected Patients

Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care

Interaction between hepatitis B virus and SARS-CoV-2 infections

Contact Info

Product

Resources

About